Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66.
In the first phase III efficacy trial of the malaria vaccine SPf66 in Africa, MOIs in SPf66- and placebo-vaccinated children were analyzed by polymerase chain reaction-restriction fragment length polymorphism of the Plasmodium falciparum merozoite surface antigen 2 (MSA2). MOIs were significantly reduced in asymptomatic vaccine recipients compared with those in asymptomatic placebo recipients; however, no differences were observed among symptomatic children in the vaccine and control groups. These results show that immunization with SPf66 modulates the course of naturally occurring infections, as reflected by reduced MOIs. In placebo recipients, however, there was a significant negative correlation between numbers of infecting genotypes, as identified by MSA2, and morbidity. Asymptomatic placebo recipients had an average of 5 concurrent infections, whereas children with clinical cases had an average of 3.4 infections. These data provide further evidence that premunition from concurrent infections is important in immunity against clinical malaria. No such effect of multiple infections was found in the vaccinated group.
Beck
H P
HP
Swiss Tropical Institute, Basel.
Felger
I
I
Huber
W
W
Steiger
S
S
Smith
T
T
Weiss
N
N
Alonso
P
P
Tanner
M
M
D000818:Animals; D000953:Antigens, Protozoan; D002675:Child, Preschool; D005838:Genotype; D006801:Humans; D007223:Infant; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000469:parasitology / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000235:genetics; D012150:Polymorphism, Restriction Fragment Length; D015800:Protozoan Proteins / Q000235:genetics; D014611:Vaccination
D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D015800:Protozoan Proteins; C065974:merozoite surface protein 2, Plasmodium